Times remain tough for private biotech venture capital funding. Access to capital is more constrained than it’s been in years, and companies are starting to feel the pinch.  Yet, despite the pain after a cycle of excess, perhaps this return

By Aoife Brennan, CEO of Synlogic, as part of the From The Trenches feature of LifeSciVC It was the last thing our finance team needed; a vague email from the CEO on a Thursday afternoon.  They were working on the

By Mike Cloonan, CEO of Sionna Therapeutics, as part of the From The Trenches feature of LifeSciVC There are a lot of reasons to be excited about leading an early-stage biotech company. It’s a chance to be at the forefront

By Jonathan Montagu, CEO of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC The phrase ‘build it and they will come’ dates all the way back to the Old Testament, and in more recent times has

Science2Startup (S2S) is back!  In April 2020, we were planning the 3rd annual S2S conference for university-focused biotech entrepreneurship – but it was unfortunately scuttled by COVID. A subsequent event in 2021 was also precluded by the pandemic.  But as

By Bob Clarke, CEO of Kinaset Therapeutics, as part of the From The Trenches feature of LifeSciVC As I ride the Amtrak towards New York City for a series of meetings on Park Avenue with bankers/analysts, face-to-face (F2F) meetings are

By Ankit Mahadevia, CEO of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC Biotwitter is great for healthy debates.  The most recent has been on the merits of the hybrid vs.an in-person model.  John Maraganore’s excellent

By Aoife Brennan, CEO of Synlogic Therapeutics, as part of the From The Trenches feature of LifeSciVC Earlier this month, I attended the J.P. Morgan 41st annual Healthcare Conference in San Francisco after a two-year hiatus. Despite the torrential rain

Today we’re thrilled to announce the acquisition of Nimbus’ allosteric Tyk2 autoimmune program by Takeda for up to $6 billion in an upfront and future milestones. As a potential best-in-class asset in the significant new therapeutic category of selective Tyk2

By Gerry Harriman and Jonathan Montagu, CSO and CEO, respectively, and co-founders of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC. HotSpot Therapeutics today announced a strategic collaboration with Abbvie to develop IRF5 transcription factor inhibitors

By Ivana Magovčević-Liebisch PhD, JD, CEO of VIGIL NEUROSCIENCE, as part of the From The Trenches feature of LifeSciVC Compared to most industries, biotech life cycles are lengthy. From R&D and clinical development to regulatory approval, it takes an average

We just held our 2022 Annual General Meeting for our investors, and a few weeks ago convened our Atlas Venture Retreat – both in person for the first time in 3 years.  Kicking off each of these meetings is our